Industry News Roche / Genentech STAT News

FDA approves Roche's oral SERD Wilserdly (giredestrant) for ESR1-mutated breast cancer

  • FDA approved Wilserdly (giredestrant), an oral selective estrogen receptor degrader, on 16 November for advanced HR-positive, HER2-negative breast cancer with an ESR1 mutation.
  • Approval rests on the evERA trial, in which the drug extended time to progression.
  • Roche calls it a potential top seller and enters a SERD class where it had lagged oncology rivals.
Points Based on public reports

The approval is for the narrower ESR1-mutant setting, but the larger prize is the early-breast-cancer filing that the company has described as pending, which would move the drug from a niche second-line option into adjuvant use. Roche arrives after other oral SERDs, so differentiation will rest on efficacy in the early setting and combination use rather than being first. Watch how it is positioned against existing ESR1-mutation options and CDK4/6 sequencing.